EPS9.02 Pseudomonas aeruginosa in sputum cultures of patients with cystic fibrosis before and during one year of elexacaftor/tezacaftor/ivacaftor

Objectives: Elexacaftor/Tezacaftor/Ivacaftor (ETI) improves outcome in patients with cystic fibrosis. To evaluate possible effects of ETI specifically on Pseudomonas aeruginosa (PA) we assessed sputum cultures and PA antibodies people CF (PwCF). Methods: At the Centre Innsbruck, PwCF had routine evaluation serum analysis before during ETI. Induced was collected in-house physiotherapy. Results from antibody status (Alkaline Protease, anti-Pseudomonas Elastase, Anti-Exotoxin A, Immunoglobulin G) were analysed local lab. at least four one year first included. Leeds criteria used to determine chronic, intermittent or no infection. result above cut off (1:500; 2.95 EU) counted positive. Basic therapy not changed. Results: Of 55 starting ETI, 30 (24 female) Reasons for exclusion treatment started another centre (8 PwCF), duration less than 4 months (9 low number culture results PwCF) respectively. initiation, (mean age 24.6, 9–39) mostly a moderate lung disease mean FEV1 61.7% (18.7–108.3%) Bhalla CT score 13.8 (5–25). This preliminary data shows, that 32.8% all samples (n = 299; 10.0 per positive, 32.7% 226; 7.5 remained Chronic infection detected 9 8 Intermittent 5 (4 3 positive). 13 17 (3 positive) positive culture. Conclusions: Our suggest particularly structural damage chronic remain chronically